Researchers conclude that patients with type 2 diabetes mellitus (T2DM) and atherosclerosis are at high risk of revascularization, acute limb ischemia (ALI) and amputation. Ticagrelor decreased this risk, but increased bleeding risk, an analysis of the THEMIS trial shows.